NovoBind Livestock Therapeutics, Vancouver, BC V6E 0C3, Canada.
University of British Columbia, Department of Biochemistry and Molecular Biology, Vancouver, BC V6T 1Z3, Canada.
Dis Aquat Organ. 2024 Oct 10;160:7-12. doi: 10.3354/dao03817.
Acute hepatopancreatic necrosis disease (AHPND) is a devastating shrimp disease caused by a binary toxin, PirAB, produced by Vibrio parahaemolyticus and other closely related bacteria. To address AHPND, over 300 unique single-domain antibodies (also known as nanobodies) derived from the VHH domains of Lama glama heavy-chain-only antibodies were raised against either PirA or PirB and characterized. Nanobodies were shortlisted based on their affinities for either PirA or PirB, their relative stability in intestinal fluids, and their ability to reduce PirAB-induced death in brine shrimp Artemia salina. From these data, a subset of nanobodies was tested for their ability to reduce AHPND in whiteleg shrimp Penaeus vannamei, and nanobodies targeting either PirA or PirB provided significant disease protection to whiteleg shrimp. These results show that nanobodies can be a new option for shrimp farmers to reduce or eliminate the impact of AHPND on their operations.
急性肝胰腺坏死病 (AHPND) 是一种由副溶血弧菌和其他密切相关的细菌产生的二元毒素 PirAB 引起的毁灭性虾病。为了解决 AHPND 问题，人们针对 PirA 或 PirB 从美洲驼的重链抗体的 VHH 结构域中产生了超过 300 种独特的单域抗体（也称为纳米抗体），并对其进行了表征。纳米抗体根据它们对 PirA 或 PirB 的亲和力、在肠道液中的相对稳定性以及在卤虫 Artemia salina 中减少 PirAB 诱导的死亡的能力进行了筛选。根据这些数据，一部分纳米抗体被测试了其在凡纳滨对虾中的减少 AHPND 的能力，针对 PirA 或 PirB 的纳米抗体为凡纳滨对虾提供了显著的疾病保护。这些结果表明，纳米抗体可以成为虾农减少或消除 AHPND 对其业务影响的新选择。
